Search clinical trials for: Expanded Access Protocol

Total 10327 results

Celgene

No longer available

Expanded Access for AG-221

Acute Myeloid Leukemia

United States
Novartis Pharmaceuticals

No longer available

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

FLT3-mutated Acute Myeloid Leukemia

Canada
Merck KGaA, Darmstadt, Germany
Pfizer

Approved for marketing

Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)

Metastatic Merkel Cell Carcinoma

France
Amgen

Completed

Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer

Spain, Czechia, Peru, Russian Federation, Austria, Lithuania, Poland, South Africa, Italy, Ukraine, Israel, Argentina, Belgium, Brazil, France, Hungary, Japan, Latvia, Panama
AbbVie

No longer available

Expanded Access to Rovalpituzumab Tesirine

Small Cell Lung Cancer
Harmony Biosciences, LLC

No longer available

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy

United States
AbbVie

No longer available

Expanded Access to ABBV-8E12

Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
Ionis Pharmaceuticals, Inc.

Approved for marketing

ATTR Expanded Access Program (EAP) by Ionis

Amyloidosis, Hereditary
Novartis Pharmaceuticals

Completed

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Polycythemia Vera

Germany, Belgium, France, Austria, Canada, Thailand, Norway, Bulgaria, Portugal, Chile, Mexico, Sweden
AbbVie

No longer available

Expanded Access to ABT-414

Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
Children's Hospital Medical Center, Cincinnati

Approved for marketing

Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome

Dravet Syndrome

United States
Armata Pharmaceuticals, Inc.

No longer available

Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic
Armata Pharmaceuticals, Inc.

No longer available

Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic
Johns Hopkins University

Terminated

Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access

End Stage Renal Disease | Hemolysis | Arteriovenous Graft

United States
Janssen Scientific Affairs, LLC

Approved for marketing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Advanced Cancers and FGFR Genetic Alterations
Mayo Clinic

Completed

Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin

Type 2 Diabetes Mellitus

United States
Hoffmann-La Roche

No longer available

Expanded Access to RXDX-105 for Cancers With RET Alterations

Cancers With RET Alterations

United States
Hoffmann-La Roche

No longer available

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Cancers With NTRK, ROS1, or ALK Gene Fusions

United States
Incyte Corporation

No longer available

Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis
Incyte Corporation

No longer available

Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma
Alexion Pharmaceuticals

Approved for marketing

Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)

Hypophosphatasia

United States, France
Jonsson Comprehensive Cancer Center
NantCell, Inc.

No longer available

Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

Ewing Sarcoma
AstraZeneca

Approved for marketing

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Non Small Cell Lung Cancer | Cancer of the Head and Neck

Poland, Germany, Hungary, United Kingdom
EpicentRx, Inc.

No longer available

Expanded Access for PSV Personalized Oncolytic Viruses (PSV)

Cancer
W. Dalton Dietrich
The Miami Project to Cure Paralysis

No longer available

Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair

Sciatic Nerve Injury

United States
Hector Hernandez

Approved for marketing

Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD

Total Parenteral Nutrition-induced Cholestasis

United States
Boehringer Ingelheim

No longer available

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Brazil
Molecular Insight Pharmaceuticals, Inc.

Approved for marketing

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Amicus Therapeutics

Approved for marketing

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Fabry Disease

United States, Australia
Cook Children's Health Care System

No longer available

Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children

Parenteral Nutrition-Associated Liver Disease

United States
WideTrial, Inc.

Available

Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)

Critical Limb Ischemia (CLI)
Pfizer

No longer available

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Advanced Breast Cancer (Female)

Canada, United States
Celgene

No longer available

Expanded Access for CC-2001

Other | Dermatologic

United States
Celgene

No longer available

Expanded Access for CC-4047

Multiple Myeloma

United States
Eisai Inc.

Approved for marketing

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

Thyroid Cancer

Brazil
ERYtech Pharma

No longer available

Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase (EAP)

Acute Lymphoblastic Leukemia

France
Novartis Pharmaceuticals

Completed

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Neuroendocrine Tumors

Germany
Boehringer Ingelheim

Approved for marketing

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Vertex Pharmaceuticals Incorporated

Approved for marketing

Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

Cystic Fibrosis
University of Sao Paulo General Hospital

Completed

Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine

Primary Biliary Cirrhosis | Ursodeoxycholic Acid

Brazil
Lytix Biopharma AS
ICON plc; Theradex

Completed

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Melanoma | Lymphoma | Cancer | Breast Cancer | Head and Neck Cancer | Triple-Negative Breast Cancer

United Kingdom, France, Norway, Belgium, Italy
Clovis Oncology, Inc.

No longer available

Rociletinib (CO-1686) USA Expanded Access Program

Non-small Cell Lung Cancer

United States
Medtronic Cardiac Rhythm and Heart Failure
Medtronic

Completed

Continued Access Protocol (CAP-AF)

Atrial Fibrillation

United States
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
Pfizer

No longer available

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

Gaucher Disease

United States, Israel
Cyclo Therapeutics, Inc.
Kerwin Research Center, LLC

No longer available

Expanded Access With Trappsol(R) Cyclo (TM) for an Individual Patient With Late Onset Alzheimer's Disease

Late Onset Alzheimer Disease
Rigel Pharmaceuticals

No longer available

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Immune Thrombocytopenic Purpura
Agios Pharmaceuticals, Inc.

Approved for marketing

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Acute Myeloid Leukemia | Relapsed Pediatric AML | Relapsed Adult AML
Novartis Pharmaceuticals

Completed

An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. (SEASCAPE)

Cushing's Disease

United States, Germany, Korea, Republic of, Spain, Thailand, Lebanon, Romania, Greece, Brazil, Russian Federation, Czechia
Celldex Therapeutics

No longer available

Individual Patient Expanded Access-Glembatumumab Vedotin

Metastatic gpNMB Expressing Triple Negative Breast Cancer

3

Subscribe